The UAE has officially authorized the use of the oral weight-loss medication Wegovy (semaglutide), marking a significant milestone as the second nation to approve this once-daily treatment. While the pill offers a new, non-injectable path for managing weight and reducing cardiovascular risks, medical professionals emphasize that it is not a "quick fix" for everyone. To qualify for a prescription, patients must undergo a rigorous medical assessment, which typically involves evaluating BMI—specifically targeting those with a BMI of 30 or higher, or those with a BMI of 27 accompanied by weight-related health complications. Beyond mere weight metrics, doctors carefully review a patient's full medical history, blood panels, and potential contraindications before moving forward.

It is essential to understand that Wegovy is strictly a prescription-only treatment that requires ongoing supervision from endocrinologists or internal medicine specialists. Doctors stress that the medication functions best as a supportive tool rather than a replacement for healthy living; lasting results depend heavily on consistent diet and physical activity. Furthermore, not everyone is a suitable candidate, particularly pregnant or breastfeeding women, or individuals with specific histories of pancreatitis, thyroid issues, or severe organ impairment. Ultimately, health experts urge the public to avoid self-medicating and instead work closely with qualified clinicians to determine if this therapy is safe and appropriate for their long-term health goals.